Radiochemotherapy in the elderly with lung cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 10, 2009, Pages 1405-1411

  Casas, Francesc ^a   Kepka, Lucyna ^b   Agarwal, Jai Prakash ^c   Dawotola, D ^d   Gaye, P M ^e   Abdel Wahab, Sherif ^f   Vashkevitch, L ^g   Saghatelyan, T ^h   Perin, B ⁱ   Jeremic, Branislav ^j  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c TATA MEMORIAL HOSPITAL   (India)

^d University of Saria   (Nigeria)

^e Dantec   (Senegal)

^f AIN SHAMS UNIVERSITY   (Egypt)

^g N Alexandrov Cancer Research Centre   (Belarus)

^h Department of Radiation Oncology   (Armenia)

ⁱ Institute of Lung Diseases   (Serbia)

^j Institute of Pulmonary Diseases   (Serbia)

more..

Author keywords

Adenocarcinoma histology; Early concurrent hyperfractionated radiotherapy; Elderly patients; Elective nodal irradiation; Limited stage small cell lung cancer; Lung cancer; Lung cancer in women; Non small cell lung cancer; Prophylactic cranial irradiation; Radiochemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PLATINUM COMPLEX; VINCRISTINE;

ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; BLOOD TOXICITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED RADIOTHERAPY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TARGETING; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SAFETY; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION INJURY; RADIATION RESPONSE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; GERIATRIC ASSESSMENT; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; SURVIVAL RATE;

EID: 70350604481     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.110     Document Type: Review

References (49)

1. San José S, Arnaiz MD, Lucas A et al. Radiation therapy alone in elderly with early stage non-small cell lung cancer. Lung Cancer 52, 149-154 (2006).
2. Werner-Wasik M, Scott C, Cox JD et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int. J. Radiat. Oncol. Biol. Phys. 48, 1475-1482 (2000).
3. Curran WJ, Scott CB, Langer CJ et al. Long-term benefit is observed in a Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410. Proc. Am. Soc. Clin. Oncol. 22, 621(2003) (Abstract 2499).
4. Schild SE, Stella PJ, Séller SM et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J. Clin. Oncol. 21, 3201-3206 (2003).
5. Rocha Lima CM, Herdon JE 2nd, Kosty M et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 94, 181-187 (2002).
6. Giorgo CG, Pappalardo A, Russo A et al. A Phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer. Anticancer Drugs 18, 713-719 (2007). (Pubitemid 47343666)
7. Jeremic B, Shibamoto Y, Milicic B et al. A Phase II study of concurrent accelerated hyperfractionated radiation therapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 44, 343-348 (1999). (Pubitemid 29205032)
8. Firat S, Pleister A, Virad RW, Gore E. Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage non-small cell lung cancer (NSCLC) Am. J. Clin. Oncol. 29, 252-257 (2006). (Pubitemid 44270933)
9. Semarau S, Klautke G, Virchow JC, Kundt G, Fietkau R. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy. Respir. Med. 102, 210-218 (2008). (Pubitemid 350296909)
10. Yuan S, Sun X, Li M et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III non-small cell lung cancer. Am. J. Clin. Oncol. 30, 239-244 (2007). • Landmark study influencing involved-field irradiation versus elective nodal irradiation in radiochemotherapy for stage III non-small-cell lung cancer (NSCLC). (Pubitemid 46884142)
11. Belbederlos J, Kepta L, Kong FM, Martel MK, Videtic G, Jeremic B. Report from the Internacional Atomic Energy Agency (IAEA) consultant's meeting on elective nodal irradiation in lung cancer: non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 72, 335-342 (2008). • Landmark study influencing elective nodal irradiation in NSCLC.
12. de Langen AJ, Raijmakers P, Riphagen I et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur. J. Cardiothorac. Surg. 29, 26-29 (2006). (Pubitemid 41831343)
13. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non small cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005). (Pubitemid 41058344)
14. Rodrigues G, Lock M, D'Souza D et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer - a systematic review. Radiother. Oncol. 71, 127-138 (2005).
15. Owonikoko TK, Ramalingam S. Small cell lung cancer in elderly patients: a review. J. Natl Compr. Canc. Netw. 6, 333-344 (2008).
16. Ramaswamy R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years; analysis of the surveillance, epidemiology, and end results database. J. Clin. Oncol. 24, 4539-4544 (2005). • Landmark study about the changing epidemiology of small-cell lung cancer (SCLC). (Pubitemid 46630948)
17. Pignon JP, Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 327, 1618-1624 (1992). • Landmark study influencing standard combined treatment of limited-disease (LD)-SCLC.
18. Jeremic B. Timing of concurrent radiotherapy and chemotherapy in limited-disease small-cell lung cancer: 'meta-analysis of meta-analyses'. Int. J. Radiat. Oncol. Biol. Phys. 64, 981-982 (2006). • Landmark editorial influencing standard combined treatment of LD-SCLC.
19. Jeremic B, Zimmermann FB, Bamberg M et al. Treatment of small cell lung cancer in the elderly. Hematol. Oncol. Clin. North Am. 18, 433-443 (2004). (Pubitemid 38496476)
20. Schild SE, Stella PJ ,Geyer SM et al. The outcome of combined-modality therapy for stage III small cell lung cancer in the elderly. J. Clin. Oncol. 21, 3201-3206 (2003).
21. Yuen AR, Zou G, Turrisi AT et al. Similar outcome of elderly patients in Intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 89, 1953-1960 (2000). • Landmark study influencing standard radiochemotherapy in elderly LD-SCLC.
22. Socinski MA, Bogart JA. Limited-stage small cell lung cancer: the current status of combined-modality therapy. J. Clin. Oncol. 25, 4137-4145 (2007).
23. Shimizu T, Sekine I, Sumi M et al. Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older. Jpn. J. Clin. Oncol. 37, 181-185 (2007). (Pubitemid 47090692)
24. Ludbrook JJ, Truong PT, MacNeil MV et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? A community-based population analysis. Int. J. Radiat. Oncol. Biol. Phys. 55, 1321-1330 (2003).
25. Okamoto H, Watanabe K, Kunikane H et al. Randomized Phase III trial of carboplatin plus etoposide vs split doses of cisplatin (P) plus etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): JCOG9702. Proc. Am. Soc. Clin. Oncol. 23, S623 (2005).
26. White SC, Lorigan P, Middleton MR et al. Randomised Phase II study of cyclophosphamide, doxorubicin and vincristine compared with single agent carboplatin in patients with poor prognosis small cell lung cancer. Cancer 92, 601-608 (2001). (Pubitemid 32735196)
27. Jeremic B, Shibamoto Y, Acimovic L et al. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a Phase II study. Cancer 82, 836-841 (1998). • Landmark study influencing radiochemotherapy in elderly LD-SCLC. (Pubitemid 28104161)
28. Westeel V, Murray N, Gelmon K et al. New combination of the old drugs for elderly patients with small-cell lung cancer: a Phase II study of the PAVE regimen. J. Clin. Oncol. 16, 1940-1947 (1998). • Landmark study influencing radiochemotherapy in elderly LD-SCLC.
29. Senan S, De Ruysscher D. Critical review of PET-CT for radiotherapy planning in lung cancer. Crit. Rev. Oncol. Hematol. 56, 345-351 (2005). (Pubitemid 41677616)
30. Videtic G, Belderbos J, Kong F-M, Kepka L, Martel MK, Jeremic B. Report from the International Atomic Energy Agency (IAEA) Consultants meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). Int. J. Radiat. Oncol. Biol. Phys. 72, 327-334 (2008). • Landmark study influencing elective nodal irradiation in SCLC.
31. Jeremic B, Shibamoto Y, Nikolic N et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J. Clin. Oncol. 17, 2092-2099 (1999). (Pubitemid 29318840)
32. Pottgen C, Eberhardt W, Stuschke M. Prophylactic cranial irradiation in lung cancer. Curr. Treat. Options Oncol. 5, 43-50 (2004). (Pubitemid 38899299)
33. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N. Engl. J. Med. 341, 476-484 (1999). • Landmark study influencing standard role of prophylactic cranial irradiation in LD-SCLC. (Pubitemid 29372887)
34. Gridelli C, Langer C, Maione P et al. Lung cancer in the elderly. J. Clin. Oncol. 25, 1898-1907 (2007).
35. Gregor A, Cull A, Stephens RJ et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and treatment of Cancer (EORTC). Eur. J. Cancer 33, 1752-1758 (1997).
36. Grosshans DR, Meyers CA, Allen PK et al. Neurocognitive function in patients with small cell lung cancer: effect of prophylactic cranial irradiation. Cancer 112, 589-595 (2008).
37. Slotman B, Faivre-Finn C, Kramer G et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N. Engl. J. Med. 357, 664-672 (2007). • Landmark study influencing standard role of prophylactic cranial irradiation in SCLC. (Pubitemid 47267236)
38. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J. Clin. Oncol. 22, 4626-4631 (2004). (Pubitemid 41185131)
39. Solomon D, Brummel-Smith K, Burgess L et al. National institutes of health consensus development conference statement geriatric assessment methods for clinical decision-making. J. Am. Geriatr. Soc. 51, 1490-1494 (1998).
40. Extermann M. Measuring comorbidity in older cancer patients. Eur. J. Cancer 36, 453-471 (2000). (Pubitemid 30136223)
41. Owonikoko TK, Ragin CC, Belani CP et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J. Clin. Oncol. 25, 5570-5577 (2007).
42. Govindan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: the past, present, and future. J. Thorac. Oncol. 3, 917-928 (2008).
43. Seiwert TY, Connell PP, Mauer AM et al. A Phase I dose-escalating study of combination permetexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer. ASCO 23(16S), (2005) (Abstract 7062).
44. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 12, 1096-1104 (2007).
45. Movsas B, Scott C, Sause W et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer: a quality-adjusted survival ana lysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies. Int. J. Radiat. Oncol. Biol. Phys. 45, 1143-1149 (1999).
46. Werner-Wasik M, Scott C, Cox JD et al. Recursive partitioning ana lysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int. J. Radiat. Oncol. Biol. Phys. 48, 1475-1482.
47. Langer C, Scott C, Byharddt R et al. Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC. Lung Cancer 29, 104 (2000) (Abstract 340).
48. Important drug warning regarding Avastin (bevacizumab) www.fda.gov/medwatch/safety/2007/Avastin-DHCP-TEF-Final-April2007.pdf.
49. European Organization for Research and treatment of cancer (EORTC) trial: a randomized controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited small cell lung cancer (SCLC) and good performance status http://groups.eortc.be/ radio/lung.htm.